Valion Bio Secures $8.45 Million in Series B and C Funding
PUBLIC · VBIOOct 27, 2026
Amount Raised
$84.5 Million
Round Type
Series B
BiotechnologyHealth Care
Investors
3i, LP
Description
Valion Bio, Inc. has successfully closed its Series B and C funding rounds, raising a total of up to $8.45 million. The Series B round included the purchase of 50 shares of Series B Preferred Stock and warrants from 3i, while the Series C funding involves an aggressive plan to raise up to $75 million. Investments will be utilized to accelerate product development.
Who to call at Valion Bio, and when
A new round usually means Valion Bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Valion Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Valion Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Valion Bio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Valion Bio
About
Valion Bio, Inc. is a Delaware corporation focused on advancing treatments for allergy, asthma, and other chronic diseases. The company aims to innovate in the MedTech industry. Valion Bio is dedicated to improving patient outcomes through targeted solutions.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Valion Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
